CN1968931A - 作为c5a拮抗剂的吡啶类似物 - Google Patents

作为c5a拮抗剂的吡啶类似物 Download PDF

Info

Publication number
CN1968931A
CN1968931A CNA2005800192053A CN200580019205A CN1968931A CN 1968931 A CN1968931 A CN 1968931A CN A2005800192053 A CNA2005800192053 A CN A2005800192053A CN 200580019205 A CN200580019205 A CN 200580019205A CN 1968931 A CN1968931 A CN 1968931A
Authority
CN
China
Prior art keywords
alkyl
compound
tetrahydroquinoline
benzyl
methane amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800192053A
Other languages
English (en)
Chinese (zh)
Inventor
N·拉尚斯
P·罗伊
Y·勒布兰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of CN1968931A publication Critical patent/CN1968931A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2005800192053A 2004-06-10 2005-06-07 作为c5a拮抗剂的吡啶类似物 Pending CN1968931A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57850004P 2004-06-10 2004-06-10
US60/578,500 2004-06-10

Publications (1)

Publication Number Publication Date
CN1968931A true CN1968931A (zh) 2007-05-23

Family

ID=35502992

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800192053A Pending CN1968931A (zh) 2004-06-10 2005-06-07 作为c5a拮抗剂的吡啶类似物

Country Status (7)

Country Link
US (2) US7429666B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758865A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008501722A (cg-RX-API-DMAC7.html)
CN (1) CN1968931A (cg-RX-API-DMAC7.html)
AU (1) AU2005251839A1 (cg-RX-API-DMAC7.html)
CA (1) CA2568673A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005121095A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
NZ570844A (en) * 2006-02-28 2011-11-25 Helicon Therapeutics Inc Therapeutic piperazines as PDE4 inhibitors
CN101553244B (zh) * 2006-07-21 2013-01-02 普罗米克斯有限公司 内膜增生和相关病状的治疗
KR20090074219A (ko) * 2006-10-04 2009-07-06 쉐링 코포레이션 트롬빈 수용체 길항제로서의 비사이클릭 및 트리사이클릭 유도체
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
CN108508130B (zh) * 2018-04-11 2020-01-17 国家烟草质量监督检验中心 一种超高效合相色谱-串联质谱技术拆分、测定手性农药甲霜灵和烯酰吗啉对映体的方法
US20240293380A1 (en) * 2021-06-16 2024-09-05 The Cleveland Clinic Foundation Protease inhibitors and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
CA2479930A1 (en) * 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
US20040014782A1 (en) * 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
US7429666B2 (en) * 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103168031A (zh) * 2010-10-20 2013-06-19 霍夫曼-拉罗奇有限公司 作为ampk活化剂的四氢喹啉衍生物

Also Published As

Publication number Publication date
EP1758865A1 (en) 2007-03-07
WO2005121095A1 (en) 2005-12-22
US20050277644A1 (en) 2005-12-15
EP1758865A4 (en) 2010-07-21
JP2008501722A (ja) 2008-01-24
US20090023774A1 (en) 2009-01-22
CA2568673A1 (en) 2005-12-22
US7429666B2 (en) 2008-09-30
AU2005251839A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
CN1043639C (zh) 新的哌啶化合物、其制备方法和含有它们的药用组合物
CN100338061C (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1214007C (zh) 环戊二烯并吲哚、含有这类化合物的组合物及治疗方法
CN1275964C (zh) 作为细胞增殖抑制剂的7－氧代吡啶并嘧啶
CN1820010A (zh) 作为γ－分泌素酶抑制剂的桥联N－芳基磺酰基哌啶
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1842526A (zh) 苯并二氮杂䓬cgrp受体拮抗剂
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
CN1630657A (zh) 脱氮嘌呤及其用途
CN1072219C (zh) 二氮杂䓬酮、其生产和用途
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1025500C (zh) 杂芳基3-氧-丙腈衍生物的制备方法
CN1913778A (zh) 趋化因子受体活性的氨基环戊基吡啶并吡嗪酮调节剂
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1918160A (zh) 用作趋化因子受体活性调节剂的新颖三环螺环衍生物
CN101068595A (zh) Cgrp受体拮抗剂
CN1968931A (zh) 作为c5a拮抗剂的吡啶类似物
CN1067892A (zh) 新的吡咯并[2，3-b]吡啶衍生物的制备方法
CN1926098A (zh) 新的脲衍生物及其医药应用
CN1209368C (zh) 新的乙酰胺衍生物及其用途
CN1022322C (zh) 稠合吡唑3-氧代-丙腈衍生物的制备方法
CN1103534A (zh) 具有抗精神病作用的化合物
CN1291186A (zh) 环酰胺化合物
CN1897941A (zh) 趋化因子受体活性的烷基氨基、芳基氨基以及氨磺酰基环戊基酰胺调节剂
CN101039718A (zh) Cgrp受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070523